Home›Trial›NCT07412288
🔬NCT07412288Phase 1RECRUITING

First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

Study Summary

This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.

Conditions
Healthy Participants
Interventions / Drugs
KT-579Placebo
View on ClinicalTrials.gov ↗
Sponsor
KYMR
Kymera Therapeutics
Protein Degradation
D38/100
Study Details
Enrollment96 participants
Primary Completion—
Lead SponsorKymera Therapeutics, Inc.
Data Retrieved2026-04-11 04:19:13.712885+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.